Androphilic protein studied histochemically in stage D2 prostatic cancer

Yamaguchi, Kunio; Sumiya, Hidenori; Fuse, Hideki; Matsuzaki, Osamu; Itô, Haruo; Ki, Jun Shimaza

doi:10.1002/1097-0142(19880401)61:7<1425::aid-cncr2820610724>3.0.co;2-b

Cited by 11 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously cytoplasmic localization of R 188 1-binding protein in benign and malignant human prostates was demonstrated by using fluorescent R 1881 [37-391. Since R 1881 binding in the cytoplasm of prostate cells is mainly attributable to the progestin-binding protein [40] which is a different molecular species from the progesterone receptor [41], it is reasonable that the stained sites were different from those of the androgen receptor. Demura et al [42] stained androgen receptor both in cytoplasm and nuclei of benign and some malignant human prostates by using a monoclonal antibody against human androgen receptors.…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates

et al. 1990

Self Cite

View full text Add to dashboard Cite

Androgen receptor was detected immunohistochemically in benign as well as malignant prostatic tissues by using a monoclonal rat anti-human androgen receptor antibody (AN 1-15). In both benign and malignant cells, the androgen receptor was exclusively localized in nuclei. In hyperplastic prostate, the androgen receptor was stained in the glandular and the stromal cells. In the gland, cells facing the lumen were stained more intensively than those adjacent to the basal membrane. In cancer tissue, receptor-positive and -negative cancer cells were intermingled. The percent of strongly positive cancer cells was correlated inversely with grade. Relapsed cells showed a low population of strongly positive cells irrespective of grade.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates

et al. 1990

Self Cite

View full text Add to dashboard Cite

show abstract

“…A number of prognostic factors for patients with metastatic prostate cancer have been reported. Age at the start of treatment, 11 performance status, 12 hemoglobin, 11 histologic grade, 13 extent of bone disease, 6 serum testosterone concentration 14 and post‐treatment PSA levels 15 have been reported to be significant prognostic factors. However, few studies have investigated the pattern of progression as a risk factor in metastatic prostate cancers during their clinical course.…”

Section: Discussionmentioning

confidence: 99%

Pattern of progression and survival in hormonally treated metastatic prostate cancer

et al. 1999

Self Cite

View full text Add to dashboard Cite

Background: Patients with prostate cancer generally respond to androgen ablation therapy, but progression to androgen-independence is frequently observed. To further evaluate disease progression, the pattern of progression and survival in hormonally treated metastatic prostate cancer was examined. Methods: One hundred and ninety-three patients with untreated metastatic prostate cancer (TxNxM1) who received endocrine therapy between 1986 and 1995 were included in the present study. The pattern of progression was evaluated in these patients. Results: One hundred and eighteen of the 193 patients (61.1%) had disease progression: 33 had local progression, 73 had distant progression and 12 had distant with local progression. Patients with only local progression had a longer interval to disease progression and longer survival than those with distant progression. The interval from disease progression to death in patients with local progression was longer than in those with distant progression. The patients whose prostate-specific antigen (PSA) had not been normalized 3 months after the start of endocrine therapy had a tendency to progression either into the prostate or into distant sites. Patients with extent of disease (EOD) scores of 3 and 4 progress, especially to distant sites, after endocrine treatment. Conclusions:In untreated metastatic prostate cancer, patients with a poor response of PSA levels and patients with a high volume of bone metastasis (i.e. EOD 3, 4) were in the high-risk group for progression, especially to distant sites. Progression into distant sites was a poor prognostic factor for patients with recurrence to endocrine therapy.

show abstract

Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma

Takeda

Akakura

Masai

et al. 1996

Cancer

View full text Add to dashboard Cite

show abstract

Androphilic protein studied histochemically in stage D2 prostatic cancer

Cited by 11 publications

References 29 publications

Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates

Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates

Pattern of progression and survival in hormonally treated metastatic prostate cancer

Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma

Contact Info

Product

Resources

About